ClinConnect ClinConnect Logo
Search / Trial NCT05491837

Effects of Intermittent Hypoxia in Upper and Lower Limb Functions in Persons With Incomplete Spinal Cord Injury

Launched by RIPHAH INTERNATIONAL UNIVERSITY · Aug 4, 2022

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a treatment called acute intermittent hypoxia (AIH) on people with incomplete spinal cord injuries (iSCI). Incomplete spinal cord injuries mean that some nerve pathways are still functioning, allowing for the potential for recovery. The researchers believe that AIH can help improve movement and balance in the arms and legs, as well as enhance overall quality of life and reduce disability. They want to learn more about how AIH affects these functions and also look at some specific health markers in participants.

To be eligible for the trial, participants must have an incomplete spinal cord injury for at least three months, be aged 18 years or older, and have a specific type of injury classified as ASIA category C or D. They should be able to walk with or without assistance and follow simple commands. However, those with complete spinal cord injuries, certain orthopedic problems, severe skin issues, or significant cognitive challenges are not eligible to participate. If you join the trial, you can expect to undergo evaluations related to your movement abilities and health, and you’ll be contributing to important research that may help others with similar conditions.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Incomplete SCI≥ 3 months(21);
  • 2. Traumatic and non-traumatic, non-progressive lesions, Aged ≥ 18 years ;
  • 3. LesionC4 and below as classified ASIA category C and D;
  • 4. Both gender
  • 5. Ability to ambulate with or without assistive devices; and
  • 6. Ability to follow verbal and visual command.
  • Exclusion Criteria:
  • 1. Participants with complete spinal cord injury;
  • 2. Unstable orthopedic injuries and joint contractures
  • 3. Osteoporosis with high risk of fracture;
  • 4. Pressure ulcers and cutaneous lesion(4)
  • 5. Cognitive impairment, severe cardiopulmonary complication such as severe breathing disorder

About Riphah International University

Riphah International University is a leading educational institution based in Pakistan, dedicated to advancing healthcare and medical research through innovative clinical trials. With a commitment to excellence in research and education, Riphah emphasizes ethical standards and scientific integrity in its clinical studies. The university collaborates with various stakeholders, including healthcare professionals and industry partners, to enhance patient outcomes and contribute to the global body of medical knowledge. Through its robust research programs, Riphah International University aims to foster a culture of inquiry and improve healthcare delivery both locally and internationally.

Locations

Islamabad, , Pakistan

Patients applied

0 patients applied

Trial Officials

Ikram Ali, Master

Principal Investigator

Riphah International University Islamabad

Waqar Ahmed Awan, PhD

Study Chair

Riphah International University Islamabad

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials